A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.

Karl Belanger,David R. Macdonald,Gregory Cairncross,Stan Gertler,Peter A. Forsyth,Susan Burdette-Radoux,Julie Bergeron,Denis Soulières,Samuel K. Ludwin,Nancy Wainman,Elizabeth Eisenhauer

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.

2003

Karl Belanger
David R. Macdonald
Gregory Cairncross
Stan Gertler
Peter A. Forsyth
Susan Burdette-Radoux
Julie Bergeron
Denis Soulières
Samuel K. Ludwin
Nancy Wainman
Elizabeth Eisenhauer

To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.

Keywords:

Anaplastic oligodendroglioma
Anesthesia
Mixed oligoastrocytoma
Oligodendroglioma
Cancer
Anaplastic carcinoma
Phases of clinical research
Topotecan
Cancer research
Pathology
Medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations